Advantage of a two-dose versus one-dose varicella vaccine in healthy non-immune teenagers and young adults.
This study was undertaken to compare the immunogenicity and reactogenicity of two vaccines based on the attenuated Oka-strain of Varicella zoster virus (VZV), in adolescents and young adults. One hundred and eighty-six subjects, aged 13 to 29 years, were randomized to one of two groups to receive a one- or a two-dose VZV vaccine. Pre- and post-vaccination blood samples were assayed for VZV-specific IgG. Solicited local and general symptoms, as well as unsolicited symptoms, were recorded post-vaccination. Seroconversion rates were 94.9% in the one-dose, and 100% in the two-dose, regimen. The two-dose vaccine elicited significantly higher geometric mean antibody titer, 392.5 vs 86.8 pfu. Transient local injection site pain was the most frequently-reported symptom per dose in both groups (one dose: 48.9%; two-dose: 32.8%). The two-dose vaccine regimen afforded the advantage of higher antibody titers and potential increased protection from disease, without significantly increased reactogenicity.
Kosuwon
P
P
Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. pensrikosuwon@hotmail.com
Sutra
S
S
Kosalaraksa
P
P
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood*; D019433:Chickenpox Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay; D005455:Fluorescent Antibody Technique; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007074:Immunoglobulin G; D011446:Prospective Studies; D013785:Thailand; D016896:Treatment Outcome
D000914:Antibodies, Viral; D019433:Chickenpox Vaccine; D007074:Immunoglobulin G